Hale P W, Poklis A
Toxicol Lett. 1984 Apr;21(1):1-8. doi: 10.1016/0378-4274(84)90215-7.
The potential cardiotoxicity of a racemic mixture of thioridazine-5-sulfoxide, an oxidative metabolite of thioridazine, was studied in the isolated, perfused rat heart. Thioridazine-5-sulfoxide (ring sulfoxide) was prepared by a new method in which a racemic mixture of the two diastereoisomeric forms of the compound was formed. Hearts from male Sprague-Dawley rats were perfused using a modified Langendorff preparation. Quinidine (31 microM) served as a positive control for the measurements of the electrocardiogram (ECG) and the heart rate. Thioridazine (13 microM) perfusion resulted in a variable heart rate and elevated S-T segment. Perfusate concentrations of the ring sulfoxide as low as 12 microM increased P-R and Q-T intervals, produced delays in A-V and ventricular conduction, premature ventricular contractions and ultimately A-V block. These findings suggest that thioridazine cardiotoxicity may be due in part to the actions of thioridazine ring sulfoxide.
在离体灌注大鼠心脏中研究了硫利达嗪(甲硫哒嗪)的氧化代谢产物硫利达嗪-5-亚砜外消旋混合物的潜在心脏毒性。硫利达嗪-5-亚砜(环亚砜)通过一种新方法制备,该方法形成了该化合物两种非对映异构体形式的外消旋混合物。使用改良的Langendorff装置灌注雄性Sprague-Dawley大鼠的心脏。奎尼丁(31微摩尔)用作心电图(ECG)和心率测量的阳性对照。灌注硫利达嗪(13微摩尔)导致心率变化和S-T段抬高。环亚砜的灌注液浓度低至12微摩尔时会增加P-R和Q-T间期,导致房室和心室传导延迟、室性早搏,并最终导致房室传导阻滞。这些发现表明,硫利达嗪的心脏毒性可能部分归因于硫利达嗪环亚砜的作用。